Tarsus Pharmaceuticals, Inc.
NASDAQ:TARSBiotechnology
+$0.29 today
- Market cap
- $3.74B
- Beta
- 0.51
- P/E (TTM)
- -55.9
- EPS (TTM)
- -$1.12
Volume 0.45M
Average 0.61M
TARS Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Tarsus Pharmaceuticals, Inc.NASDAQ: TARS
Gross Profit · Q3 FY2026 · quarter ended Sep 2026
Gross profit turns negative
Q3 FY2026 gross profit was -$451.5M, compared with $94.1M a year earlier. Trailing-twelve-month gross profit was $3.7M. Over 3 fiscal years it compounded at +156.7% a year.
Context
- Gross profit amounted to 93.2% of revenue in FY2025, up 0.2 pp from a year earlier.
- Gross profit increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly gross profit holds near -$451.5M or moves back toward the trailing-twelve-month quarterly average of $924.25K.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 420.68M USD
- Year-over-year change
- +147.3%
- 4-year CAGR
- +66.3%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 420.68M | +147.3% |
| FY2024 | 2024-12-31 | 170.13M | +973.1% |
| FY2023 | 2023-12-31 | 15.85M | -36.2% |
| FY2022 | 2022-12-31 | 24.86M | -54.8% |
| FY2021 | 2021-12-31 | 54.95M | — |
Gross Profit vs competitors
How TARS compares with its peers on the latest reported figures
- TARS's LTM Sep 2026 gross profit of $3.7M is the 5th highest of the 6 companies compared; the peer median is $33.27M.
- Its year-over-year change of -98.9% is the lowest of 5, against a peer median of +85.6%.
- Gross profit amounts to 0.5% of revenue for TARS, versus a peer median of 90.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $422.89M | +80.2% | +387.3% | 91.1% | |
| LTM Mar 2026 | $199.11M | +25.5% | +47.9% | 74.1% | |
| LTM Mar 2026 | $33.27M | +545.5% | +57.0% | 89.5% | |
| LTM Mar 2026 | $18.47M | +91.1% | — | 100.0% | |
| LTM Sep 2026 | $3.7M | -98.9% | +156.7% | 0.5% | |
TTRXTurn Therapeutics Inc. | LTM Mar 2026 | -$42.29K | — | — | — |
| Peer median (excluding TARS) | $33.27M | +85.6% | +57.0% | 90.3% | |
Competitors are the stored peer set for TARS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 57.03M | 25.82M | 17.45M | 182.95M | 451.36M |
| Cost of Revenue | 2.08M | 955K | 1.59M | 12.83M | 30.68M |
| Gross Profit | 54.95M | 24.86M | 15.85M | 170.13M | 420.68M |
| Gross Margin | 96.4% | 96.3% | 90.9% | 93.0% | 93.2% |
| Research & Development | 41.71M | 42.62M | 50.31M | 53.39M | 64.32M |
| Selling, General & Admin | 25.4M | 44.95M | 108.7M | 237.31M | 427.32M |
| Operating Expenses | 67.11M | 87.57M | 159.01M | 290.7M | 491.65M |
| Depreciation & Amortization | 312K | 326K | 877K | 1.23M | 1.82M |
| EBITDA | (13.46M) | (59.71M) | (131.67M) | (106.48M) | (53.61M) |
| EBITDA Margin | -23.6% | -231.3% | -754.7% | -58.2% | -11.9% |
| Operating Income | (12.16M) | (62.71M) | (143.16M) | (120.57M) | (70.97M) |
| Operating Margin | -21.3% | -242.9% | -820.5% | -65.9% | -15.7% |
| Interest Income | 36K | 3.5M | 10.34M | 15.01M | 15.75M |
| Interest Expense | 0 | 2.06M | 3.23M | 7.45M | 8.94M |
| Other Income / Expenses | (1.62M) | 617K | 7.27M | 5.02M | 6.61M |
| Income Before Tax | (13.77M) | (62.1M) | (135.89M) | (115.55M) | (64.36M) |
| Pre-Tax Margin | -24.1% | -240.5% | -778.9% | -63.2% | -14.3% |
| Income Tax Expense | 55K | (4K) | 0 | 0 | 2.06M |
| Net Income | (13.83M) | (62.09M) | (135.89M) | (115.55M) | (66.42M) |
| Net Margin | -24.2% | -240.5% | -778.9% | -63.2% | -14.7% |
| EPS (Basic) | (0.67) | (2.52) | (4.62) | (3.07) | (1.59) |
| EPS (Diluted) | (0.67) | (2.52) | (4.62) | (3.07) | (1.59) |
| Weighted Avg Shares | 20.55M | 24.62M | 29.38M | 37.6M | 41.78M |
| Weighted Avg Shares (Diluted) | 20.55M | 24.62M | 29.38M | 37.6M | 41.78M |
Tarsus Pharmaceuticals, Inc.
NASDAQ:TARS
Intrinsic Alpha fair value
Locked
Current Price
$75.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.